For Australian Healthcare Professionals
What has shingles cost
Rosalyn ?
She hadn ’ t anticipated she ’ d get shingles and was unprepared for its impact on her daily life . †
†
Rosalyn , aged 55 , is a fictional case study . Person appearing is a model and for illustrative purposes only .
Your patients aged ≥50 years are likely to be at risk of shingles , no matter how healthy they may feel 1 – 4 *
* Immunocompromise in people aged 18 years and older , caused by immunosuppressant drugs or immunodeficient conditions , may also increase the risk of shingles .
Scan the QR code to learn more about SHINGRIX
Indication 5 : SHINGRIX is indicated for the prevention of herpes zoster ( HZ ) and post-herpetic neuralgia in : adults 50 years of age or older , and in adults 18 years of age or older at increased risk of HZ .
Contraindication 5 : Hypersensitivity to the active substances or to any component of the vaccine .
PBS Information : SHINGRIX is listed on the National Immunisation Program ( NIP ) for Aboriginal and Torres Strait Islander adults aged ≥50 years , for all individuals aged ≥65 years and for adults aged ≥18 years with some immunocompromising medical risk conditions . Refer to NIP schedule or your State or Territory Health department .
Please review Product Information before prescribing . Product Information can be accessed at www . gsk . com . au / shingrix or by scanning the QR code .
This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
References : 1 . Weinberg A , et al . J Infect Dis . 2010 ; 201 ( 7 ): 1024 – 30 . 2 . Centers for Disease Control and Prevention ( CDC ). Prevention of herpes zoster : recommendations of the Advisory Committee on Immunization Practices ( ACIP ). MMWR . 2008 June ; 57 ( RR-5 ): 1-30 . 3 . Australian Technical Advisory Group on Immunisation ( ATAGI ). Australian Immunisation Handbook , Australian Government Department of Health and Aged Care , Canberra , 2022 . Available at : immunisationhandbook . health . gov . au [ Accessed August 2024 ] 4 . Gidding HF , et al . Epidemiol Infect . 2003 ; 131 ( 3 ): 1085 – 9 . 5 . SHINGRIX Approved Product Information .
For information on GSK products or to report an adverse event involving a GSK product , please contact GSK Medical Information on 1800 033 109 . GlaxoSmithKline Australia Pty Ltd . ABN 47 100 162 481 . Melbourne , VIC . Trade marks are owned by or licensed to the GSK group of companies . © 2024 GSK group of companies or its licensor . PM-AU-SGX-JRNA-240011 . Date of approval : September 2024 .
Recombinant Varicella Zoster Virus glycoprotein E antigen ( AS01B adjuvanted vaccine )